Moxifloxacin plus standard first-line therapy in the treatment of pulmonary tuberculosis: A meta-analysis

Tuberculosis

Volumn 95, Issue 4, 2015, Pages 490-496

  Chen, Zhi ^a   Liang, Jian Qin ^a   Wang, Jin He ^a   Feng, Shi Sheng ^a   Zhang, Guang Yu ^a  

^a No 309 PLA Hospital   (China)

Author keywords

Chemotherapy; First line therapy; Meta analysis; Moxifloxacin; Pulmonary tuberculosis

Indexed keywords

AMINOTRANSFERASE; ETHAMBUTOL; ISONIAZID; MOXIFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; QUINOLONE DERIVATIVE; TUBERCULOSTATIC AGENT;

ACUTE KIDNEY FAILURE; ARTHRALGIA; ARTICLE; BACTERIUM CULTURE; BLURRED VISION; CARDIOTOXICITY; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEVER; GASTROINTESTINAL SYMPTOM; GOUT; HUMAN; HYPERURICEMIA; LIVER DYSFUNCTION; LUNG TUBERCULOSIS; META ANALYSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; UPPER GASTROINTESTINAL BLEEDING; ADULT; AGED; DRUG COMBINATION; DRUG EFFECTS; FEMALE; MALE; MICROBIOLOGY; MIDDLE AGED; ODDS RATIO; PATHOGENICITY; REMISSION; TIME; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY;

ADULT; AGED; ANTITUBERCULAR AGENTS; DRUG THERAPY, COMBINATION; FEMALE; FLUOROQUINOLONES; HUMANS; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; ODDS RATIO; REMISSION INDUCTION; TIME FACTORS; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY;

EID: 84931574227     PISSN: 14729792     EISSN: 1873281X     Source Type: Journal    
DOI: 10.1016/j.tube.2015.03.014     Document Type: Article

References (21)

1. 2004. World health report 2004: changing history. WHO. Geneva, Switzerland. http://www.who.int/whr/2004/en/report04-en.pdf.
2. 2007. Global tuberculosis control - surveillance, planning, financing. WHO. Geneva, Switzerland. http://www.who.int/tb/publications/global-report/2007/download-centre/en/index.html.
3. C. Dye, C.J. Watt, and D. Bleed Low access to a highly effective therapy: a challenge for international tuberculosis control Bull World Health Organ 80 2002 437 444
4. D.B. Young, M.D. Perkins, K. Duncan, and C.E. Barry 3rd Confronting the scientific obstacles to global control of tuberculosis J Clin Invest 118 2008 1255 1265
5. R.G. Hall, R.D. Leff, and T. Gumbo Treatment of active pulmonary tuberculosis in adults: current standards and recent advances. Insights from the society of infectious diseases pharmacists Pharmacotherapy 29 2009 1468 1481
6. R. Dawson, and A. Diacon PA-824, moxifloxacin and pyrazinamide combination therapy for tuberculosis Expert Opin Investig Drugs 22 2013 927 932
7. World Health Organization Guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update 2011 World Health Organization Geneva Available at: http://whqlibdoc.who.int/publications/2011/9789241501583-eng.pdf [accessed 11.13.14]
8. World Health Organization Global tuberculosis control 2008-surveillance, planning, financing 2008 WHO/HTM/TB/2008.393 Geneva Available at: file:///C:/Users/Elizabeth/Downloads/moz-Global-tuberculosis-control-2008.pdf [accessed 11.13.14]
9. J.H. Grosset, T.G. Singer, and W.R. Bishai New drugs for the treatment of tuberculosis: hope and reality Int J Tuberc Lung Dis 16 2012 1005 1014
10. J.P.T. Higgins Cochrane collaboration handbook for systematic reviews of interventions version 5.1.0 [updated 03.11] 2011 The Cochrane Collaboration Available from: www.cochrane-handbook.org 2011
11. D.A. Mitchison Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months Am Rev Respir Dis 147 1993 1062 1063
12. A.J. Sutton, S.J. Duval, R.L. Tweedie, K.R. Abrams, and D.R. Jones Empirical assessment of effect of publication bias on meta-analyses Bmj 320 2000 1574 1577
13. J.Y. Wang, J.T. Wang, T.H. Tsai, C.L. Hsu, C.J. Yu, and P.R. Hsueh Adding moxifloxacin is associated with a shorter time to culture conversion in pulmonary tuberculosis Int J Tuberc Lung Dis 14 2010 65 71
14. M.B. Conde, A. Efron, C. Loredo, G.R. De Souza, N.P. Graça, and M.C. Cezar Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial Lancet 373 2009 1183 1189
15. R. Rustomjee, C. Lienhardt, T. Kanyok, G.R. Davies, J. Levin, and T. Mthiyane A phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis Int J Tuberc Lung Dis 12 2008 128 138
16. W.J. Burman, S. Goldberg, J.L. Johnson, G. Muzanye, M. Engle, and A.W. Mosher Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis Am J Respir Crit Care Med 174 2006 331 338
17. Jawahar MS, Banurekha VV, Paramasivan CN, Rahman F, Ramachandran R, Venkatesan P, et al. Randomized clinical trial of thrice-weekly 4-month moxifloxacin or gatifloxacin containing regimens in the treatment of new sputum positive pulmonary tuberculosis patients. PLoS ONE;8(7):e67030.
18. N Engl J Med 2014;371:1577-1587.
19. Gillespie SH, Crook AM, McHugh TD, Mendel CM, Meredith SK, Murray SR, et al. Four-Month Moxifloxacin-Based Regimens for Drug-Sensitive Tuberculosis.
20. L.E. Ziganshina, A.F. Titarenko, and G.R. Davies Fluoroquinolones for treating tuberculosis (presumed drug-sensitive) Cochrane Database Syst Rev 6 2013 CD004795
21. W.M. el-Sadr, D.C. Perlman, J.P. Matts, E.T. Nelson, D.L. Cohn, and N. Salomon Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG) Clin Infect Dis 26 1998 1148 1158